The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

November 17, 2022

Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of increased access to high-quality screening, and the need for more inclusive research efforts to close the gaps in breast cancer diagnosis and care.

November 15, 2022

Future advances in melanoma and other skin cancers should focus on team-oriented care and increasingly informed treatment sequencing regarding the roles of immunotherapy, targeted therapy, and surgery.

November 02, 2022

Institutional Perspectives in Cancer: Melanoma - Chaired by Carlo Contreras, MD

October 24, 2022

Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.

October 13, 2022

Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.

September 28, 2022

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

August 12, 2022

Anne M. Noonan, MBBCh, discusses prominent new therapies in hepatocellular carcinoma, the benefits of immunotherapy in gastric cancer, chemotherapy developments in pancreatic cancer, and the importance of considering HER2-targeted therapy in metastatic colorectal cancer.

July 26, 2022

John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.

July 26, 2022

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

July 11, 2022

John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.

July 08, 2022

John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.

June 22, 2022

Institutional Perspectives in Cancer- GI: Chaired by Anne M Noonan, MBBCh

June 20, 2022

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

May 18, 2022

The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

April 20, 2022

David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.

March 22, 2022

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.

March 16, 2022

January 31, 2022

Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.

January 27, 2022

Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.

January 17, 2022

Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.